The awareness and recognition of PPD, and getting women and families access to treatment, remains critically important. Earlier this year Sarah Acaster co-authored a paper with Sage Therapeutics on the relationship between patient reported outcomes and clinician-reported outcomes used in PPD trials. This new paper applies some of these findings to support the interpretation of data from three clinical trials of brexanolone injection.
The aim was to present clinical trial data in a format more accessible or informative for real-world and shared decision making, including outcomes such as individual patient-level sustained response and number needed to treat. Similar outcomes, also exploring broader symptoms such as sleep and anxiety, have been presented throughout the year at various virtual conferences, based on the treatment’s oral formulation, so look out for more publications in the coming months.